A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.

MLA

Martínez-Cuadrón, David, et al. “A Precision Medicine Test Predicts Clinical Response after Idarubicin and Cytarabine Induction Therapy in AML Patients.” Leukemia Research, vol. 76, Jan. 2019, pp. 1–10. EBSCOhost, https://doi.org/10.1016/j.leukres.2018.11.006.

APA

Martínez-Cuadrón, D., Gil, C., Serrano, J., Rodríguez, G., Pérez-Oteyza, J., García-Boyero, R., Jiménez-Bravo, S., Vives, S., Vidriales, M. B., Lavilla, E., Pérez-Simón, J. A., Tormo, M., Colorado, M., Bergua, J., López, J. A., Herrera, P., Hernández-Campo, P., Gorrochategui, J., Primo, D., … Montesinos, P. (2019). A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. Leukemia Research, 76, 1–10. https://doi.org/10.1016/j.leukres.2018.11.006

Chicago

Martínez-Cuadrón, David, Cristina Gil, Josefina Serrano, Gabriela Rodríguez, Jaime Pérez-Oteyza, Raimundo García-Boyero, Santiago Jiménez-Bravo, et al. 2019. “A Precision Medicine Test Predicts Clinical Response after Idarubicin and Cytarabine Induction Therapy in AML Patients.” Leukemia Research 76 (January): 1–10. doi:10.1016/j.leukres.2018.11.006.